Published in Circulation on December 21, 2009
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (2012) 4.87
Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. Am J Hum Genet (2009) 2.04
Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels. Arterioscler Thromb Vasc Biol (2010) 1.79
Comparative analysis of genome-wide association studies signals for lipids, diabetes, and coronary heart disease: Cardiovascular Biomarker Genetics Collaboration. Eur Heart J (2011) 1.73
Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase. J Am Coll Cardiol (2016) 1.49
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J Lipid Res (2012) 1.46
Rationale for cholesteryl ester transfer protein inhibition. Curr Opin Lipidol (2012) 1.15
HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther (2012) 0.92
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol (2016) 0.92
Translating genomics into improved healthcare. BMJ (2010) 0.92
Gene-environment interactions of CETP gene variation in a high cardiovascular risk Mediterranean population. J Lipid Res (2010) 0.85
Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. Int J Epidemiol (2016) 0.85
The role of advanced lipid testing in the prediction of cardiovascular disease. Curr Atheroscler Rep (2014) 0.82
The Active for Life Year 5 (AFLY5) school-based cluster randomised controlled trial: effect on potential mediators. BMC Public Health (2016) 0.80
Developing treatments for pulmonary arterial hypertension. Pulm Circ (2013) 0.77
Harnessing publicly available genetic data to prioritize lipid modifying therapeutic targets for prevention of coronary heart disease based on dysglycemic risk. Hum Genet (2016) 0.75
A phenome-wide association study of a lipoprotein-associated phospholipase A2 loss-of-function variant in 90 000 Chinese adults. Int J Epidemiol (2016) 0.75
Vulnerable plaque: from bench to bedside; local pacification versus systemic therapy. Heart Views (2012) 0.75
Measuring inconsistency in meta-analyses. BMJ (2003) 128.20
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol (2003) 16.71
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet (2007) 15.27
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med (2008) 9.39
Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med (2007) 6.79
Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet (2008) 6.06
A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet (2008) 4.75
Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA (2008) 4.21
Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med (2004) 3.49
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet (2007) 2.65
Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol (2004) 2.64
Estimation of bias in nongenetic observational studies using "mendelian triangulation". Ann Epidemiol (2006) 2.57
Nature's randomised trials. Lancet (2005) 2.53
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med (2007) 2.41
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J (2008) 2.26
Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol (2008) 2.13
Polymorphism in the CETP gene region, HDL cholesterol, and risk of future myocardial infarction: Genomewide analysis among 18 245 initially healthy women from the Women's Genome Health Study. Circ Cardiovasc Genet (2009) 1.92
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation (2008) 1.91
Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study. Circ Cardiovasc Genet (2009) 1.83
New functional promoter polymorphism, CETP/-629, in cholesteryl ester transfer protein (CETP) gene related to CETP mass and high density lipoprotein cholesterol levels: role of Sp1/Sp3 in transcriptional regulation. Arterioscler Thromb Vasc Biol (2000) 1.42
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol (2006) 1.42
Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J Lipid Res (2003) 1.32
Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol (2005) 1.30
CETP inhibitors to increase HDL cholesterol levels. N Engl J Med (2007) 1.27
Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit. Effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J Clin Invest (1989) 1.16
Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem (1998) 1.15
High-density genotyping and functional SNP localization in the CETP gene. J Lipid Res (2006) 0.89
An overview of 37 randomised trials of blood pressure lowering agents among 270,000 individuals. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Clin Exp Hypertens (1999) 0.78
Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med (2008) 57.29
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science (2007) 37.88
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation (2008) 26.42
Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet (2008) 25.83
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
GenABEL: an R library for genome-wide association analysis. Bioinformatics (2007) 18.10
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet (2010) 16.96
Genome-wide association analysis identifies 20 loci that influence adult height. Nat Genet (2008) 16.92
'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol (2003) 16.71
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25
Replicating genotype-phenotype associations. Nature (2007) 16.11
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 15.64
Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med (2006) 15.60
C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med (2004) 15.30
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Priority actions for the non-communicable disease crisis. Lancet (2011) 15.18
Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med (2010) 14.49
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet (2007) 13.76
Vitamin D deficiency and risk of cardiovascular disease. Circulation (2008) 13.39
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation (2007) 12.79
Obesity and the risk of heart failure. N Engl J Med (2002) 12.58
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet (2008) 12.32